Inhalation Science

Breathing Simulation Testing

Reproduce realistic breathing profiles to quantify inhaled and respirable dose, emissions, and device-interface effects under defined use conditions.

Programmable breathing simulators reproduce adult and pediatric profiles using mouth/nose fixtures. Cascade impactors or filters collect the dose for quantitation by HPLC, ELISA, or ddPCR, as defined in the study plan.

ISO 17025USP <601>USP <1601>FDA MDI / DPI / nasalReviewed 2026-05-15
Request a quoteSubmit a sample

Purpose & when to use

Breathing Simulation Testing uses a programmable pump to reproduce human inhalation profiles, including tidal volume, flow rate, and breath duration, while measuring the inhaled and respirable dose delivered through a device interface. Compendial configurations align with USP <601> and USP <1601>. Adult and pediatric profiles can be programmed within the framework of ISO 27427 and FDA MDI / DPI / nasal guidance. Common uses include:

  1. Inhaled dose comparisons across MDIs, DPIs, nebulizers, and soft-mist inhalers — profile-resolved dose datasets aligned to USP <601> and FDA MDI / DPI / nasal guidance for submission and change-control packages.
  2. Pediatric-to-adult profile mapping for inhalation and intranasal products — bracketing use-condition variability across age-scaled tidal volumes and flow rates under FDA pediatric-study guidance.
  3. Mask and valved holding chamber (VHC) interface-effect studies — quantifying leakage, dead-space, and coordination impacts under ISO 27427 nebulizing-equipment and FDA MDI / DPI guidance framing.
  4. Respirable-fraction estimation by pairing breathing simulation with [cascade impactor PSD](/testing-services/particle-aerosol-measurement/psd-testing/) — links device emissions to predicted lung deposition under USP <601> aerodynamic-size framing.
  5. Sensitivity and profile-variability mapping across breathing conditions, actuation timing, and device orientation — supports ICH Q9 risk-assessment and FDA change-control packages.

Use breathing simulation when inhaled-dose data must reflect realistic use conditions, such as adult or pediatric profiles, interface variability, or device comparisons. Under the defined study conditions, the resulting dataset can support engineering decisions, regulatory submissions, or risk-assessment packages.

Built for inhalation and intranasal drug delivery devices

Breathing simulation characterises performance across the device classes where realistic use conditions — patient breathing pattern, interface geometry, and actuation timing — drive the dose the patient receives.

  • MDIMetered-dose inhalers
  • DPIDry-powder inhalers
  • NebulizerLiquid aerosol generators
  • Nasal sprayIntranasal pump delivery
  • Spacer / VHCValved holding chambers

Instrumentation & measurement ranges

Platform selection depends on the device class, breathing profile, and regulatory frame. The study plan confirms each component, and the method report records the final configuration.

5 – 100 L/mininhalation-flow

Programmable breathing simulator (ASL 5000 or equivalent)

Piston-driven breathing pump with programmable tidal volume, flow rate, and breath duration — adult and pediatric profiles selectable; profile fidelity verified against the set waveform before each campaign.

0.1 – 5 sinhalation-duration

Adult and pediatric mouth/nose fixtures and headforms

USP-geometry induction ports, adult/pediatric nose-throat models, and headform-style interfaces — geometry matched to the device class and the patient population under study.

0.4 – 11 µmaerodynamic

Cascade impactors and filter-based collection (NGI / Andersen)

Downstream dose collection via NGI or Andersen cascade impactor stages, or a validated filter assembly — collection method selected to match the size-fraction and dose endpoint required.

0.1 – 1000 µgper-profile

Analytical quantitation suite (HPLC, ELISA, qPCR / ddPCR)

HPLC for small-molecule actives, ELISA for protein analytes, and qPCR / ddPCR for nucleic-acid actives — assay matched to the active and matrix, with system suitability and recovery documented per assay.

Test method options

MethodStrengthsTradeoffAligned with
Compendial-aligned breathing simulation (USP <601> / <1601>)
  • Submission-grade inhaled-dose datasets under defined fixtures and breathing profiles — the canonical USP <601> and USP <1601> compendial package for inhalation characterisation.
  • Documented acceptance logic and statistical framing for FDA MDI / DPI / nasal submissions, lifecycle changes, and predicate comparisons.
Strict configuration control and documentation overhead — best when device and formulation are locked enough to justify the filing-bound setup cost.
USP <601>USP <1601>FDA MDI / DPI / nasal
Interface and mask effects study (fixture sweep)
  • Directly measures mask, spacer, and VHC leakage effects on inhaled dose — answers the interface-sensitivity question FDA MDI / DPI guidance requires.
  • Controlled fixture protocol surfaces dose differences attributable to interface geometry alone, isolating interface impact from device variability.
Careful fixture fabrication and leak-check protocol needed to avoid measurement artifacts that obscure real interface effects.
FDA MDI / DPI / nasalISO 27427
User-variability mapping (breathing profile sweep)
  • Brackets realistic breathing-pattern variability from pediatric low-flow to adult high-flow profiles — supports ICH Q9 risk-assessment and FDA change-control packages.
  • Profile-resolved dose dataset directly informs device-label guidance (optimal flow rate, coordination requirements) and user-group selection rationale.
More profiles increase replicate count and study duration — scope tightly to the profile range that drives the specific decision.
ICH Q9FDA MDI / DPI / nasal
Emissions-to-exposure translation (fit for purpose)
  • Links device emissions to breathing-zone inhaled dose under defined scenarios — supports exposure assessment beyond the compendial collection endpoint.
  • Pairs with emitted-dose data to build a full dose-to-patient picture; framing aligned to FDA CMC guidance for consumer and medical devices.
Requires explicit scenario definition and documented assumptions — results are scenario-specific and must be scoped carefully to avoid over-generalisation.
FDA MDI / DPI / nasal

Setup configurations

Study configurations are matched to the device, patient population, and regulatory frame. The setup must reproduce the specified tidal volume, flow rate, and breath duration while remaining compatible with the collection train and quantitation method. During study planning, ARE Labs confirms the following variables for each campaign:

Device interfaces

Mouthpiece adapters, USP induction ports, adult/pediatric nose-throat models, and headform interfaces — geometry matched to the device class and the target patient population.

Flow & actuation profiles

Programmable tidal volume, peak flow rate, and inhalation duration — adult and pediatric waveforms logged against the set profile before each campaign with actuation timing synchronised to breath phase.

Sample numbers

Replicates per device and per profile — power sized to declared within-profile and device-to-device variability with documented statistical framing.

Media & handling

Collection-media selection (filter or impactor stages), extraction-solvent compatibility, and documented storage and chain of custody for collected fractions.

Environmental controls

Temperature and humidity conditioning when formulation or device performance is known to be sensitive — equilibration and environmental monitoring logged alongside dose collection.

Compliance frame for inhalation breathing simulation

Breathing simulation studies operate within a documented quality system grounded in the pharmacopoeial and regulatory frameworks for inhalation and intranasal products. The four anchors below define the quality and documentation requirements carried through the §7 outputs.

  • ISO 17025AccreditedTesting-laboratory competence — documented methods, calibration traceability, and uncertainty contributors.
  • USP <601>AccreditedInhalation and nasal drug products — performance quality tests with breathing-simulation provisions.
  • USP <1601>AlignedProducts for nebulization — characterization tests including breathing-simulator methods.
  • FDA MDI / DPI / nasalAlignedChemistry, manufacturing, and controls plus breathing-pattern testing for inhalation submissions.

Key data outputs & reporting

The final report presents inhaled-dose results by profile and condition, repeatability statistics, and the underlying datasets. ARE Labs formats these materials for submission packages, change-control documentation, or engineering decisions. Primary deliverables include profile-resolved dose data, interface-sensitivity comparisons, and respirable-fraction context. Profile verification logs, fixture leak checks, assay calibration records, and other traceable QA / QC documentation are maintained throughout the study and provided with the report.

Primary outputs

  • Inhaled and respirable dose by breathing profile and condition — mean, SD, and CV across replicates, with profile-to-profile comparisons.
  • Interface sensitivity data — dose delta attributable to mask, spacer, or VHC geometry, with documented fixture-leak controls.
  • Assay calibration, recovery, and uncertainty contributors documented alongside results for inspection-readiness.

Deliverables

#FormatContents
01PDF reportMethods, breathing-profile setup, controls, statistical framing, and acceptance logic.
02CSV / XLSX datasetsPer-profile inhaled dose, replicate statistics, and condition deltas.
03FiguresDose-versus-profile plots, condition overlays, and interface-sensitivity charts for internal review and submission appendices.

QA / QC & data integrity

QA / QC controls are scaled to the method plan and documented for each breathing simulation study. The selected checks address the required profile fidelity, collection train, and analytical method, and they run alongside dose collection. Records are audited under our ISO 17025 quality system and remain traceable from sample receipt through the final result.

Profile verification logs — breathing-simulator waveform confirmed against the set tidal volume, flow rate, and duration before each campaign and between condition blocks.

Fixture leak checks before and after each collection series — documented to bound leakage contribution to dose uncertainty.

Blanks and background controls for collection media, with stage and filter blanks run alongside device measurements.

Assay controls — calibration standards, system suitability per assay, and spike-recovery on matrix-challenging analytes across HPLC, ELISA, and ddPCR endpoints.

Chain of custody from sample receipt through collection, extraction, quantitation, and final reporting.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Inhalation and intranasal product teams often ask about profile selection, pediatric testing, interface effects, quantitation, and deliverables while scoping a breathing simulation study. The answers below provide a starting point. If your device class, patient population, or regulatory frame is not represented, contact ARE Labs to discuss the setup. Most studies require at least one custom configuration decision, which is usually easier to resolve before the method plan is finalized.

Q.Can you run pediatric and adult breathing profiles in the same study?
A.Yes. We can program adult and pediatric profiles within the same campaign and report dose metrics for each profile. This approach produces an age-bracketed dataset from one physical device campaign that may support pediatric regulatory submissions, depending on the study design and submission requirements.
Q.How do you measure inhaled dose from the breathing simulator?
A.Dose is collected downstream of the mouth/nose interface with a filter or cascade impactor. ARE Labs then quantifies the collected material by HPLC, ELISA, or ddPCR, matched to the active and matrix. Controls, blanks, and recovery are documented for each assay.
Q.Can you evaluate mask and spacer interface effects?
A.Yes. Mask and VHC effects are common study objectives. ARE Labs runs controlled fixture sweeps, documents leak checks, and compares dose across interface geometries while controlling device variability.
Q.Is breathing simulation only for pharmaceutical products?
A.No. Breathing simulation can also quantify inhaled dose for consumer and medical devices when realistic breathing conditions affect the exposure assessment. The same simulator and collection methods are used, with the study designed around the relevant regulatory or engineering decision.
Q.What do I receive at the end of the study?
A.Deliverables include a PDF report covering setup assumptions, profile logs, controls, and statistical framing; CSV / XLSX datasets with per-profile dose and replicate statistics; and figures comparing dose across profiles and conditions.

Standards & guidance

ARE Labs aligns breathing simulation studies with the pharmacopoeial, consensus, and regulatory standards that govern inhaler characterisation and inhalation product submissions. When third-party accreditation covers the scope, the method is identified as accredited, including ISO 17025 and USP <601>. When a standard is followed without formal accreditation, the method is described as aligned or conformant where applicable. The cards below identify the standards most often used for breathing simulation packages.

Inhalation & Drug Delivery - Accredited

USP <601>

Inhalation and nasal drug products — performance quality tests with breathing-simulation provisionsView standard ->Inhalation & Drug Delivery - Aligned

USP <1601>

Products for nebulization — characterization tests including breathing-simulator methodsView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Chemistry, manufacturing, controls, and breathing-pattern testing for inhalation and intranasal submissionsView standard ->Inhalation & Drug Delivery - Aligned

ISO 27427

Anaesthetic and respiratory equipment — nebulizing systems and components using breathing simulatorsView standard ->QA & Regulatory - Aligned

ICH Q9

Quality risk management — risk-assessment and profile-variability framing for breathing simulation studiesView standard ->

Related services & devices

Service

Particle Size Distribution (PSD) Testing

Pairs with breathing simulation for inhalation submissions — stage-by-stage aerodynamic size data contextualises the respirable fraction of inhaled dose.Read more ->Service

Dose Uniformity & Emitted Dose Testing

Complement to breathing simulation — per-actuation emitted dose under controlled flow, providing the device-output baseline the simulator builds on.Read more ->Devices

Respiratory Drug Delivery Devices

MDI, DPI, and nebulizer programs — breathing simulation characterises real-world dose delivery across the inhalation device portfolio.Read more ->Devices

Intranasal Delivery Devices

Nasal pumps and unit-dose devices — breathing simulation with nose-throat models quantifies interface effects and realistic intranasal dose.Read more ->